ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Systematic Review of Continuous Glucose Monitoring and Its Effect on Quality of Life in Type 2 Diabetes Mellitus.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous Glucose Monitoring (CGM) has transformed diabetes management by providing real-time glucose data, improving glycemic control, and potentially influencing patient well-being. However, the extent to which CGM affects health-related quality of life (HR-QoL) in individuals with type 2 diabetes mellitus (T2DM) remains unclear. This systematic review aimed to evaluate the effects of CGM on QoL and glycemic outcomes in adults with T2DM by comparing CGM use with conventional self-monitoring of blood glucose (SMBG). A systematic literature search was conducted in March 2025 across Scopus, MEDLINE, and EBSCO databases. Eligible studies included adult T2DM patients using CGM (flash or real-time), reported QoL and HbA1c outcomes, and provided a control group. Out of 1525 identified records, five studies met the inclusion criteria. CGM was consistently associated with greater HbA1c reduction than SMBG, with two studies reporting statistically significant improvements. However, most studies showed no significant difference in QoL between CGM and control groups, except for one study reporting psychological benefit. Methodological quality was moderate, with JADAD scores ranging from 2 to 3. In conclusion, CGM use in T2DM patients is associated with improved glycemic control and may provide psychological benefits, although its overall impact on QoL remains inconclusive. Further long-term studies using diabetes-specific QoL tools are needed to better understand the broader implications of CGM on patient-centered outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.